Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
samedi, novembre 21
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Cardlytics Inc
CDLX
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$1.05
-0.06
-5.41%
À la clôture: Nov 20, 4:00 PM EST
Get Report
Aperçu
Actualités
Graphiques
Prévisions de résultats
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Cardlytics Financials
Cardlytics (CDLX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Cardlytics Q3 Adj. EPS $(1.03) Beats $(1.04) Estimate, Sales $32.882M Miss $36.350M Estimate
Cardlytics (NASDAQ:CDLX) reported quarterly losses of $(1.03) per share which beat the analyst consensus estimate of $(1.04) by 0.96 percent. This is a 47.14 percent decrease over losses of $(0.70) per share from the
Benzinga Newsdesk
PRO
Cardlytics Sees Q4 Sales $35.000M-$39.000M vs $41.150M Est
Cardlytics (NASDAQ:CDLX) sees Q4 sales of $35.000 million-$39.000 million vs $41.150 million analyst estimate.
Benzinga Newsdesk
PRO
Cardlytics Sees Q3 Sales $34.000M-$39.000M vs $38.594M Est
Cardlytics (NASDAQ:CDLX) sees Q3 sales of $34.000 million-$39.000 million vs $38.594 million analyst estimate.
Benzinga Newsdesk
PRO
Cardlytics Q2 Adj. EPS $(0.81) Beats $(1.35) Estimate, Sales $36.882M Miss $37.003M Estimate
Benzinga Newsdesk
PRO
Cardlytics Sees Q2 Sales $35.000M-$40.000M vs $37.519M Est
Cardlytics (NASDAQ:CDLX) sees Q2 sales of $35.000 million-$40.000 million vs $37.519 million analyst estimate.
Benzinga Newsdesk
PRO
Cardlytics Q1 Adj. EPS $(0.11) Beats $(0.21) Estimate, Sales $34.319M Miss $37.200M Estimate
Cardlytics (NASDAQ:CDLX) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.21) by 47.62 percent. This is a 47.62 percent increase over losses of $(0.21) per share from the
Benzinga Newsdesk